Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatmentXochitl C. Morgan, Curtis Huttenhower, Timothy L. Tickle et al.|Genome biology|2012Cited by 2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Axel Dignaß, Amanda Ricciuto et al.|Gastroenterology|2021Cited by 2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Joannie Ruel, David T. Rubin et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in MiceGraham J. Britton, Jeremiah J. Faith, Eduardo J. Contijoch et al.|Immunity|2019Cited by 553
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Peter M. Irving et al.|The Lancet|2022Cited by 295